Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04473781 · ClinicalTrials.gov registry record · Phase 1
Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
A Phase 1 study of Stage II Renal Cell Cancer and Stage I Renal Cell Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04473781 is a Phase 1 study of Stage II Renal Cell Cancer and Stage I Renal Cell Cancer that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 17 participants, below the 111-participant average among 4 other Stage II Renal Cell Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04473781, a Phase 1 study of Stage II Renal Cell Cancer and Stage I Renal Cell Cancer, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients with kidney cancer that have refused or are unable to undergo surgery or ablation (unresectable/unablatable). Brachytherapy, also known as internal radiation therapy, temporarily introduces a radiation source into or near the tumor to eradicate the tumor cells. Giving brachytherapy may potentially reduce the size of the kidney cancer mass that would otherwise not be amenable to surgical management and translate into lower risk of spread.
Conditions Studied
Interventions
- PROCEDURE Interstitial Radiation Therapy
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04473781
The ClinicalTrials.gov registry entry for NCT04473781 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 4 other Stage II Renal Cell Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage II Renal Cell Cancer appearing as the primary indexed condition, and to 1 intervention - of which Interstitial Radiation Therapy is the first listed.
NCT04473781 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04473781 about?
NCT04473781 is a clinical study titled "Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer". This phase I/II trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients with kidney cancer that have refused or are unable to undergo surgery or ablation (unresectable/unablatable). Brachytherapy,...
What is the current status of trial NCT04473781?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-07-16. Estimated completion is 2027-06-30.
What conditions does trial NCT04473781 study?
This clinical trial studies the following conditions: Stage II Renal Cell Cancer, Stage I Renal Cell Cancer.
What interventions are being tested in trial NCT04473781?
The interventions under investigation include: Interstitial Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT04473781?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04473781 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Renal Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
RECRUITING · Phase 1
-
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
RECRUITING · Phase 2
-
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
ACTIVE NOT RECRUITING
-
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.